Artiva Biotherapeutics, Inc.

Contributing Author

Recent Articles by Artiva Biotherapeutics, Inc.

Nov-12	Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease ARTV GlobeNewswire
Nov-12	Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights ARTV GlobeNewswire
Nov-03	Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK ARTV GlobeNewswire
Oct-30	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November ARTV GlobeNewswire
Oct-16	Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update ARTV GlobeNewswire
Aug-25	Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 ARTV GlobeNewswire
Aug-06	Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights ARTV GlobeNewswire
May-28	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference ARTV GlobeNewswire
May-13	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting ARTV GlobeNewswire
May-08	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights ARTV GlobeNewswire